Soma Sengupta

American Brain Tumor Association Announces $1.3 Million in New Funding to Accelerate Adult and Pediatric Brain Tumor Research

Retrieved on: 
Mercoledì, Novembre 8, 2023
Soma, American Brain Tumor Association, Biomarker, Neuro, History, MD, Soma Sengupta, ABTA, Research, Chapel Hill, Mount Sinai, Brain, DNA repair, Icahn School of Medicine at Mount Sinai, Patient, Doctor of Philosophy, Joel, DNA, Medical imaging, Pharmaceutical industry, Citrus

CHICAGO, Nov. 8, 2023 /PRNewswire/ -- The American Brain Tumor Association (ABTA) today announced the funding of $1.37 million towards 23 new research grants to advance brain tumor science and treatments, across all brain tumor types and ages. Dedicated to advancing the field of neuro-oncology and accelerating the discovery of life-saving treatments, the ABTA is proud to have invested more than $35 million, to approximately 700 researchers and 800 projects, to date.

Key Points: 
  • CHICAGO, Nov. 8, 2023 /PRNewswire/ -- The American Brain Tumor Association (ABTA) today announced the funding of $1.37 million towards 23 new research grants to advance brain tumor science and treatments, across all brain tumor types and ages.
  • ABTA's high-risk, high-reward research grants have contributed to significant breakthroughs in treating brain tumors.
  • This year's slate of research projects investigates biomarkers, DNA damage and repair mechanisms, gene therapies, and more, across adult and pediatric primary brain tumors and metastatic brain cancers.
  • Research Collaboration Grants are two-year, $200,000 grants awarded for multi-investigator and multi-institutional brain tumor collaborative research projects.